Secukinumab
- PDF / 151,253 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 9 Downloads / 151 Views
1 S
Drug hypersensitivity reaction: case report An adult woman in her 30s developed delayed-type drug hypersensitivity reactions during treatment with secukinumab for axial spondyloarthritis. The woman at the age of 24 years, diagnosed with axial spondyloarthritis in February 2016. She was commenced on diclofenac and sulfasalazine, however, it showed poor response. Therefore, from December 2017, she started receiving secukinumab injection. Later, for six months her condition was stable. However, after receiving 14th injection of secukinumab in June 2018, she developed a low-grade fever and intermittent abdominal discomfort. Then, abdominal CT scan and esophagogastroduodenoscopy was performed, which showed no abnormalities. One month later, she received her 15th injection of secukinumab, subsequently, she developed a diffused rash on the lower limbs, fever and abdominal discomfort, and required hospitalisation. Thereafter, her liver function test showed mildly elevated aspartate aminotransferase (35 U/L), all other blood tests were normal. Her infection workup was negative for any type of infections. Thereafter, she was diagnosed with drug hypersensitivity reactions. Therefore, her treatment with secukinumab was stopped, and one month later, her symptoms completely resolved. Her drug hypersensitivity reactions did not occur immediately after first exposure, it occurred after multiple doses were administered. Therefore, it was considered as delayed-type drug hypersensitivity reactions. Wong SCT, et al. Secukinumab-Induced Delayed-Type Drug Hypersensitivity Reactions. JCR: Journal of Clinical Rheumatology 26: e197-e198, No. 6, Sep 2020. Available 803522886 from: URL: http://doi.org/10.1097/RHU.0000000000001065
0114-9954/20/1835-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Dec 2020 No. 1835
Data Loading...
